Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O5S |
Molecular Weight | 365.404 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(OC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CCC=CC3)C(O)=O
InChI
InChIKey=RDMOROXKXONCAL-UEKVPHQBSA-N
InChI=1S/C16H19N3O5S/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/6998373
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373
Cefroxadine is an antibiotic developed for the treatment of bacterial infectious diseases caused by gram-negative and gram-positive organisms. The information about drug status is unavailable and is supposed to be "discontinued", however it may be manufactured in Italy by Novartis.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory]. | 2004 Dec |
|
A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean. | 2006 Feb 13 |
Sample Use Guides
The daily dosage of 1000mg should be divided into 2 fractions and should be taken after breakfast and after supper.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373
The spectrum of antibacterial activity of cefroxadine against gram-positive and gram-negative bacteria was studied. About 0.005 ml of diluted culture was inoculated by Micro-planter onto agar plates containing a series of serial twofold dilutions of a drug. The concentration of the drug required to inhibit the growth of 50% of the total number of tested E. coli strains (MIC50) was 3.13 to 6.25 ug/ml. The MIC50 of cefroxadine against K. pneumoniae strains was 3.13 to 6.25 ug/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
||
|
WHO-ATC |
J01DB11
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
||
|
WHO-VATC |
QJ01DB11
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C012671
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
31379
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
51762-05-1
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
100000081831
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL3186538
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
B908C4MV2R
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
557
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
DB11367
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
4722
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
m3215
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
257-391-8
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
DTXSID1022768
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
SUB07419MIG
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
C81033
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
Cefroxadine
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY | |||
|
5284529
Created by
admin on Sat Dec 16 16:01:29 GMT 2023 , Edited by admin on Sat Dec 16 16:01:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY